Literature DB >> 20618220

Cellulose acetate beads activate the complement system but inactivate the anaphylatoxins generated.

Yuji Takeda1, Masahiro Ohba, Masamichi Ueno, Abbi R Saniabadi, Ichiro Wakabayashi.   

Abstract

The generation of anaphylatoxins, particularly C5a, is important in extracorporeal circulation therapies such as granulocyte/monocyte apheresis, which activates the complement system and elevates C5a levels. However, no side effects of granulocyte/monocyte apheresis using cellulose acetate beads have been reported. To investigate the mechanism of complement activation, we prepared plasma from cellulose acetate bead-treated blood (P-CAB) and compared it with zymosan-activated plasma (ZAP). Anaphylaxis activity was measured by skin test, and the activity of carboxypeptidase, which inactivates C5a, was measured by colorimetric assay. Pro-carboxypeptidase R and neutrophil elastase concentrations were measured by enzyme-linked immunosorbent assay. Although C5a was generated in P-CAB, the anaphylaxis activity of P-CAB was lower than that of ZAP. Carboxypeptidase activity and pro-carboxypeptidase R levels were suppressed in P-CAB, but not in ZAP. Furthermore, neutrophil elastase levels increased in P-CAB. The decreases in carboxypeptidase activity and inactivation of anaphylatoxin were inhibited by a neutrophil elastase inhibitor. These results suggest that cellulose acetate beads initiate the activation of carboxypeptidase R via elastase release, thereby inducing the inactivation of anaphylatoxin.
© 2010, Copyright the Authors. Artificial Organs © 2010, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20618220     DOI: 10.1111/j.1525-1594.2009.00995.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  1 in total

1.  Inhibition of CXCL10 release by monomeric C3bi and C4b.

Authors:  Y Takeda; K Kaneda; F Jimma; N Shiobara; M Hidaka; A R Saniabadi; I Wakabayashi
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.